1. Medicines
  2. Oncology
  3. TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in Melanoma

Prescribing information

 

Tafinlar + Mekinist

_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Tafinlar in combination with Mekinist is indicated in adult patients for the treatment of BRAF V600 positive, unresectable or metastatic melanoma, and in the adjuvant setting for Stage III BRAF V600 positive melanoma, following complete resection.1,2

Please select either treatment of BRAF-positive metastatic melanoma or adjuvant treatment of Stage III BRAF-positive melanoma below to find out more; then, consider treatment from a patient perspective by clicking on ‘Management of patients with BRAF positive melanoma’.

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
Rate this content: 
No votes yet
TMC20-C004 May 2020
Oncology
Product
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com